Recombinant Mouse TIGIT Protein (Fc Tag)(Active)
SKU: PKSM040427-100
Recombinant Mouse TIGIT Protein (Fc Tag)(Active)
| SKU # | PKSM040427 |
| Expression Host | HEK293 Cells |
Description
| Synonyms | T-cell immunoreceptor with Ig and ITIM domains, TIGIT, V-set and transmembrane domain-containing protein 3, VSTM3 |
| Species | Mouse |
| Expression Host | HEK293 Cells |
| Sequence | Met1-Gly141 |
| Accession | PP86176 |
| Calculated Molecular Weight | 39.8 kDa |
| Observed Molecular Weight | 52 kDa |
| Tag | C-hFc |
| Bio-activity | Immobilized mouse PVR-His at 10 μg/ml (100 μl/well) can bind mouse TIGIT-Fc, The EC50 of mouse TIGIT-Fc is 0.25-0.55 μg/ml. |
Properties
| Purity | > 90 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-10 and diminished the production of IL-12p40. In addition, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.